Pila Pharma AB Company
Pila Pharma AB is developing a new class of orally active drugs for the treatment of newly diagnosed type 2 diabetes. PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden. PILA PHARMA is developing a novel type of oral anti-diabetic agent: a TRPV1 antagonist for the treatment of diabetes. The company owns issued use-patents giving the right to treat diabetes and obesity with TRPV1 antagonists. Our safe clinical development candidate, XEN-D0501, entered the first clinical trials in type-2 diabetic patients in 2017.
Industry:
Geroscience
Headquarters:
Malmö, Skane Lan, Sweden
Zip:
1-10
Founded Date:
2014-01-01
Employees Number:
1-10
Acquisitions Number:
2
Investors Number:
81868
Total Funding:
Less than $1M
Estimated Revenue:
Less than $1M
Last Funding Date:
Grant
Last Funding Type:
Grant
Register and Claim Ownership